1
|
Gou L, Yue GGL, Puno PT, Lau CBS. A review on the relationship of mast cells and macrophages in breast cancer - Can herbs or natural products facilitate their anti-tumor effects? Pharmacol Res 2020; 164:105321. [PMID: 33285235 DOI: 10.1016/j.phrs.2020.105321] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Revised: 11/05/2020] [Accepted: 11/21/2020] [Indexed: 12/27/2022]
Abstract
Breast cancer is an inflammation-related cancer whose tumor microenvironment is largely infiltrated by inflammatory cells. These inflammatory cells including mast cells and macrophages have been elucidated to be vital participants in breast tumor proliferation, survival, invasion and migration. However, the functions of mast cells and macrophages in breast cancer are quite distinct based on recent data. Mast cells exhibit both anti-tumoral and pro-tumoral functions on breast cancer, while high number of tumor-associated macrophages (TAMs) are strongly correlated with poor prognosis and higher risk of distant metastasis in breast cancer patients. Besides, many natural products/extracts have been reported to regulate mast cells and macrophages. In this review, the roles of mast cells and macrophages play in breast cancer are discussed and a summary of those natural products/herbs regulating the functions of mast cells or macrophages is also presented.
Collapse
Affiliation(s)
- Leilei Gou
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, Yunnan, China; University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Grace Gar-Lee Yue
- Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, HKSAR, China; State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Shatin, New Territories, HKSAR, China
| | - Pema Tenzin Puno
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, Yunnan, China.
| | - Clara Bik-San Lau
- Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, HKSAR, China; State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Shatin, New Territories, HKSAR, China.
| |
Collapse
|
2
|
Liskova A, Koklesova L, Samec M, Varghese E, Abotaleb M, Samuel SM, Smejkal K, Biringer K, Petras M, Blahutova D, Bugos O, Pec M, Adamkov M, Büsselberg D, Ciccocioppo R, Adamek M, Rodrigo L, Caprnda M, Kruzliak P, Kubatka P. Implications of flavonoids as potential modulators of cancer neovascularity. J Cancer Res Clin Oncol 2020; 146:3079-3096. [PMID: 32902794 DOI: 10.1007/s00432-020-03383-8] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 09/01/2020] [Indexed: 02/06/2023]
Abstract
PURPOSE The formation of new blood vessels from previous ones, angiogenesis, is critical in tissue repair, expansion or remodeling in physiological processes and in various pathologies including cancer. Despite that, the development of anti-angiogenic drugs has great potential as the treatment of cancer faces many problems such as development of the resistance to treatment or an improperly selected therapy approach. An evaluation of predictive markers in personalized medicine could significantly improve treatment outcomes in many patients. METHODS This comprehensive review emphasizes the anticancer potential of flavonoids mediated by their anti-angiogenic efficacy evaluated in current preclinical and clinical cancer research. RESULTS AND CONCLUSION Flavonoids are important groups of phytochemicals present in common diet. Flavonoids show significant anticancer effects. The anti-angiogenic effects of flavonoids are currently a widely discussed topic of preclinical cancer research. Flavonoids are able to regulate the process of tumor angiogenesis through modulation of signaling molecules such as VEGF, MMPs, ILs, HIF or others. However, the evaluation of the anti-angiogenic potential of flavonoids within the clinical studies is not frequently discussed and is still of significant scientific interest.
Collapse
Affiliation(s)
- Alena Liskova
- Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
| | - Lenka Koklesova
- Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
| | - Marek Samec
- Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
| | - Elizabeth Varghese
- Department of Physiology and Biophysics, Weill Cornell Medicine in Qatar, Education City, Qatar Foundation, Doha, 24144, Qatar
| | - Mariam Abotaleb
- Department of Physiology and Biophysics, Weill Cornell Medicine in Qatar, Education City, Qatar Foundation, Doha, 24144, Qatar
| | - Samson Mathews Samuel
- Department of Physiology and Biophysics, Weill Cornell Medicine in Qatar, Education City, Qatar Foundation, Doha, 24144, Qatar
| | - Karel Smejkal
- Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic
| | - Kamil Biringer
- Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
| | - Martin Petras
- Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia
| | - Dana Blahutova
- Department of Biology and Ecology, Faculty of Education, Catholic University in Ruzomberok, Ruzomberok, Slovakia
| | | | - Martin Pec
- Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01, Martin, Slovakia
| | - Marian Adamkov
- Department of Histology and Embryology, Jessenius Faculty of Medicine, Comenius University, Martin, Slovakia
| | - Dietrich Büsselberg
- Department of Physiology and Biophysics, Weill Cornell Medicine in Qatar, Education City, Qatar Foundation, Doha, 24144, Qatar.
| | - Rachele Ciccocioppo
- Gastroenterology Unit, Department of Medicine, Azienda Ospedaliera Universitaria Integrata Policlinico GB Rossi, University of Verona, Verona, Italy
| | - Mariusz Adamek
- Department of Thoracic Surgery, Faculty of Medicine and Dentistry, Medical University of Silesia, Katowice, Poland
| | - Luis Rodrigo
- Faculty of Medicine, University of Oviedo, Central University Hospital of Asturias (HUCA), Oviedo, Spain
| | - Martin Caprnda
- 1st Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital, Bratislava, Slovakia
| | - Peter Kruzliak
- 2nd Department of Surgery, Faculty of Medicine, Masaryk University, Pekarska 53, 656 91, Brno, Czech Republic. .,St. Anne's University Hospital, Brno, Czech Republic.
| | - Peter Kubatka
- Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, 036 01, Martin, Slovakia.
| |
Collapse
|
3
|
Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, Johnson GL, Anders CK. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro Oncol 2018; 19:1481-1493. [PMID: 28486691 DOI: 10.1093/neuonc/nox052] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Background Triple-negative breast cancer (TNBC), lacking expression of hormone and human epidermal growth factor receptor 2 receptors, is an aggressive subtype that frequently metastasizes to the brain and has no FDA-approved systemic therapies. Previous literature demonstrates mitogen-activated protein kinase kinase (MEK) pathway activation in TNBC brain metastases. Thus, we aimed to discover rational combinatorial therapies with MEK inhibition, hypothesizing that co-inhibition using clinically available brain-penetrant inhibitors would improve survival in preclinical models of TNBC brain metastases. Methods Using human-derived TNBC cell lines, synthetic lethal small interfering RNA kinase screens were evaluated with brain-penetrant inhibitors against MEK1/2 (selumetinib, AZD6244) or phosphatidylinositol-3 kinase (PI3K; buparlisib, BKM120). Mice bearing intracranial TNBC tumors (SUM149, MDA-MB-231Br, MDA-MB-468, or MDA-MB-436) were treated with MEK, PI3K, or platelet derived growth factor receptor (PDGFR; pazopanib) inhibitors alone or in combination. Tumors were analyzed by western blot and multiplexed kinase inhibitor beads/mass spectrometry to assess treatment effects. Results Screens identified MEK+PI3K and MEK+PDGFR inhibitors as tractable, rational combinations. Dual treatment of selumetinib with buparlisib or pazopanib was synergistic in TNBC cells in vitro. Both combinations improved survival in intracranial SUM149 and MDA-MB-231Br, but not MDA-MB-468 or MDA-MB-436. Treatments decreased mitogen-activated protein kinase (MAPK) and PI3K (Akt) signaling in sensitive (SUM149 and 231Br) but not resistant models (MDA-MB-468). Exploratory analysis of kinome reprogramming in SUM149 intracranial tumors after MEK ± PI3K inhibition demonstrates extensive kinome changes with treatment, especially in MAPK pathway members. Conclusions Results demonstrate that rational combinations of the clinically available inhibitors selumetinib with buparlisib or pazopanib may prove to be promising therapeutic strategies for the treatment of some TNBC brain metastases. Additionally, effective combination treatments cause widespread alterations in kinase pathways, including targetable potential resistance drivers.
Collapse
Affiliation(s)
- Amanda E D Van Swearingen
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Maria J Sambade
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Marni B Siegel
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Shivani Sud
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Robert S McNeill
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Samantha M Bevill
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Xin Chen
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Ryan E Bash
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Louisa Mounsey
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Brian T Golitz
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Charlene Santos
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Allison Deal
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Joel S Parker
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Naim Rashid
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - C Ryan Miller
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Gary L Johnson
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Carey K Anders
- Lineberger Comprehensive Cancer Center, Departments of Genetics, Pharmacology, Pathology & Laboratory Medicine, Laboratory Animal Medicine, Biostatistics, and Medicine, Divisions of Neuropathology, Hematology/Oncology, School of Medicine, and Neurology and Neurosciences Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| |
Collapse
|
5
|
Di Desidero T, Xu P, Man S, Bocci G, Kerbel RS. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. Oncotarget 2015; 6:42396-410. [PMID: 26623560 PMCID: PMC4767441 DOI: 10.18632/oncotarget.6377] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 11/16/2015] [Indexed: 12/21/2022] Open
Abstract
Metronomic chemotherapy has shown promising activity in numerous preclinical studies and also some phase II clinical studies involving various tumor types, and is currently undergoing phase III trial evaluation. Triple-negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options and very poor prognosis following progression after standard chemotherapeutic regimens. Herein, we evaluated the potential therapeutic impact and molecular mechanisms of topotecan administered in a continuous low-dose metronomic (LDM) manner, alone or in concurrent combination with pazopanib, an antiangiogenic tyrosine kinase inhibitor (TKI), in a triple-negative, primary and metastatic breast cancer orthotopic model; potential molecular mechanisms of efficacy were also studied, especially the impact of hypoxic conditions. The combination of metronomic topotecan and pazopanib significantly enhanced antitumor activity compared to monotherapy with either drug and prolonged survival, even in the advanced metastatic survival setting, with a marked decrease in tumor vascularity, proliferative index, and the induction of apoptosis. Significant changes in tumor angiogenesis, cancer cell proliferation, apoptosis, HIF1α levels, HIF-1 target genes and ABCG2 were found both in vitro and in tumor tissue. Notably, the pazopanib and metronomic topotecan combination treatment inhibited expression of HIF1α and ABCG2 genes in cells grown under hypoxic conditions, and this was associated with an increased intracellular concentration of the active form of topotecan. Our results suggest a potential novel therapeutic option for the treatment of metastatic triple-negative breast cancer patients.
Collapse
Affiliation(s)
- Teresa Di Desidero
- Biologic Sciences Platform, Sunnybrook Research Institute, Toronto, Canada
- Divisione di Farmacologia, Dipartimento di Medicina Clinica e Sperimentale, University of Pisa, Pisa, Italy
| | - Ping Xu
- Biologic Sciences Platform, Sunnybrook Research Institute, Toronto, Canada
| | - Shan Man
- Biologic Sciences Platform, Sunnybrook Research Institute, Toronto, Canada
| | - Guido Bocci
- Divisione di Farmacologia, Dipartimento di Medicina Clinica e Sperimentale, University of Pisa, Pisa, Italy
| | - Robert S. Kerbel
- Biologic Sciences Platform, Sunnybrook Research Institute, Toronto, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, Canada
| |
Collapse
|